Crossover Study on the Effect of Omegaven in Combination With Different Lipid Emulsions in Home Parenteral Nutrition

A Prospective, Randomized, Controlled, Double-blind, Crossover-Design, Mono-center, Phase IV Study Comparing the Effect of Omegaven in Combination With Clinoleic or Lipoplus or SMOFlipid in Home Parenteral Nutrition Patients

The aim of this study was to evaluate the safety and tolerance of ClinOleic or Lipoplus or SMOFlipid lipid emulsions. After 6 weeks of each lipid emulsion, Omegaven (fish oil) was added for a further 4 weeks. The safety and tolerance was evaluated after each lipid emulsion cycle by biochemistry, hematology and coagulation variables, vital signs and adverse events. We also analysed fatty acid profiles in plasma or erythrocyte phospholipids, antioxidant enzyme activities, lipid peroxidation products, plasma lipids and pro-inflammatory cytokine production after in vitro stimulation of whole blood by lipopolysacharide in HPN patients. The non-interventional group of healthy controls was included for comparison.

Study Overview

• Status: Completed
• Conditions: Parenteral Nutrition
• Intervention / Treatment: Drug: ClinOleic (baseline); Drug: ClinOleic + Omegaven; Drug: Lipoplus (baseline); Drug: Lipoplus + Omegaven; Drug: SMOFlipid (baseline); Drug: SMOFlipid + Omegaven

Detailed Description

Intravenous lipid emulsions (LEs) are an indispensable part of home parenteral nutrition (HPN). All commercially obtainable LEs are applicable for HPN in providing a source of energy and essential fatty acids. The originally used soyabean oil-based LE (Intralipid) have been suspected of being associated with a higher risk of pro-inflammatory lipid-mediator production due to their high content of n-6 polyunsaturated fatty acids. The more modern mixes of soyabean oil, and/or olive oil, and/or fish oil LEs with beneficial responses compared with Intralipid are available. Given that there are no clear clinical recommendations for LE application in HPN, we performed this cross-over design, phase 4 study comparing ClinOleic, Lipoplus or SMOFlipid in chronic intestinal failure patients with additional escalation of fish oil using Omegaven.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 4

Contacts and Locations

Study Locations

• Czechia
  • Prague, Czechia, 12808
    • General University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Home parenteral nutrition patients in need of parenteral nutrition administration > 4 days/week
• Parenteral duration expectancy > 8 months
• Stable clinical condition without any complications in the past 2 months
• Written consent from the subject

Exclusion Criteria:

• Known hypersensitivity to any of the active substances or excipients
• Unstable conditions
• Active cancer or its treatment
• Established immunodeficiency
• Advanced organ dysfunction from chronic disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1 Home Parenteral Nutrition, Cross-over; Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.	Drug: ClinOleic (baseline); Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: ClinOleic 20% Baxter; Drug: ClinOleic + Omegaven; Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: ClinOleic 20% Baxter + Omegaven 10% Fresenius Kabi; Drug: Lipoplus (baseline); Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: Lipoplus 20% BBraun Melsungen; Drug: Lipoplus + Omegaven; Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: Lipoplus 20% BBraun Melsungen + Omegaven 10% Fresenius Kabi; Drug: SMOFlipid (baseline); Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: SMOFlipid 20% Fresenius Kabi; Drug: SMOFlipid + Omegaven; Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: SMOFlipid 20% Fresenius Kabi + Omegaven 10% Fresenius Kabi
Active Comparator: 2 Home Parenteral Nutrition, Cross-over; Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.	Drug: ClinOleic (baseline); Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: ClinOleic 20% Baxter; Drug: ClinOleic + Omegaven; Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: ClinOleic 20% Baxter + Omegaven 10% Fresenius Kabi; Drug: Lipoplus (baseline); Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: Lipoplus 20% BBraun Melsungen; Drug: Lipoplus + Omegaven; Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: Lipoplus 20% BBraun Melsungen + Omegaven 10% Fresenius Kabi; Drug: SMOFlipid (baseline); Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: SMOFlipid 20% Fresenius Kabi; Drug: SMOFlipid + Omegaven; Lipid emulsion in pharmacy compounded all-in-one admixture; Other Names: SMOFlipid 20% Fresenius Kabi + Omegaven 10% Fresenius Kabi
No Intervention: Comparator3; Healthy Control

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline lipid emulsion production of TNF-alpha after in vitro stimulation of whole blood by lipopolysacharide at 4 weeks of Omegaven lipid emulsion addition	The whole blood culture supernatant concentration of TNF-alpha (ng/L)	day 42, day 70
Change from baseline lipid emulsion production of IL-1-beta after in vitro stimulation of whole blood by lipopolysacharide at 4 weeks of Omegaven lipid emulsion addition	The whole blood culture supernatant concentration of IL-1-beta (ng/L)	day 42, day 70
Change from baseline lipid emulsion production of IL-6 after in vitro stimulation of whole blood by lipopolysacharide at 4 weeks of Omegaven lipid emulsion addition	The whole blood culture supernatant concentration of IL-6 (ng/L)	day 42, day 70
Change from baseline lipid emulsion production of IL-8 after in vitro stimulation of whole blood by lipopolysacharide at 4 weeks of Omegaven lipid emulsion addition	The whole blood culture supernatant concentration of IL-8 (ng/L)	day 42, day 70

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline lipid emulsion plasma concentration of TNF-alpha at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of TNF-alpha (ng/L)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of IL-1-beta at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of IL-1-beta (ng/L)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of IL-6 at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of IL-6 (ng/L)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of IL-8 at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of IL-8 (ng/L)	day 42, day 70
Change from baseline lipid emulsion plasma concentration ratio of oxidized LDL/LDL cholesterol at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration ratio of oxidized LDL/LDL cholesterol (ox-LDL/LDL-C)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of triglycerides at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of triglycerides (mmol/L)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of total cholesterol at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of total cholesterol (mmol/L)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of HDL cholesterol at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of HDL cholesterol (mmol/L)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of LDL cholesterol at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of LDL cholesterol (mmol/L)	day 42, day 70
Change from baseline lipid emulsion plasma phospholipid fatty acid profile at 4 weeks of Omegaven lipid emulsion addition	The plasma phospholipid fatty acid profile (mol%)	day 42, day 70
Change from baseline lipid emulsion erythrocyte phospholipid fatty acid profile at 4 weeks of Omegaven lipid emulsion addition	The erythrocyte phospholipid fatty acid profile (mol%)	day 42, day 70
Change from baseline lipid emulsion plasma concentration of fibrothelial growth factor 19 at 4 weeks of Omegaven lipid emulsion addition	The plasma concentration of fibrothelial growth factor 19 (ng/L)	day 42, day 70
Change from baseline lipid emulsion erythrocyte superoxide dismutase activity at 4 weeks of Omegaven lipid emulsion addition	The erythrocyte activity of SOD (U/g Hb)	day 42, day 70
Change from baseline lipid emulsion erythrocyte catalase activity at 4 weeks of Omegaven lipid emulsion addition	The erythrocyte activity of CAT (U/g Hb)	day 42, day 70
Change from baseline lipid emulsion erythrocyte glutathione peroxidase activity at 4 weeks of Omegaven lipid emulsion addition	The erythrocyte activity of GPX (U/g Hb)	day 42, day 70
Change from baseline lipid emulsion erythrocyte glutathione reductase activity at 4 weeks of Omegaven lipid emulsion addition	The erythrocyte activity of GR (U/g Hb)	day 42, day 70
Change from baseline lipid emulsion plasma paraoxonase 1 activity at 4 weeks of Omegaven lipid emulsion addition	The plasma activity of PON1 (U/L)	day 42, day 70
Alteration of liver function	Liver function tests	week 6, week 10, week 16, week 20, week 26, week 30
Septic complications	Catheter-related bloodstream infections	week 6, week 10, week 16, week 20, week 26, week 30

Collaborators and Investigators

• Sponsor: General University Hospital, Prague
• Collaborators: Charles University, Czech Republic; Ministry of Health, Czech Republic
• Investigators: Principal Investigator: Frantisek Novak, MD, PhD, General University Hospital, Prague

Study record dates

Study Major Dates

• Study Start (Actual): January 15, 2012
• Primary Completion (Actual): January 7, 2016
• Study Completion (Actual): June 30, 2016

Study Registration Dates

• First Submitted: April 11, 2017
• First Submitted That Met QC Criteria: May 9, 2017
• First Posted (Actual): May 11, 2017

Study Record Updates

• Last Update Posted (Actual): May 11, 2017
• Last Update Submitted That Met QC Criteria: May 9, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Keywords: olive oil; lipid emulsion; fish oil; home parenteral nutrition; intestinal failure
• Additional Relevant MeSH Terms: Pharmaceutical Solutions; Parenteral Nutrition Solutions; Fat Emulsions, Intravenous; SMOFlipid
• Other Study ID Numbers: NT13236-4/2012

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No